- Investing.com
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. The company’s lead product candidate is ersodetug, a human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 2 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Analyst Outlook | Discover varied analyst perspectives on Rezolute, with price targets ranging from $7 to $9, reflecting the company's growth potential in metabolic diseases. |
Market Opportunities | Learn about Rezolute's potential in niche markets, including congenital hyperinsulinism and diabetic macular edema, with oral administration as a key advantage. |
Financial Strength | Delve into Rezolute's robust financial position, with $118 million in cash and a strong current ratio, supporting ongoing clinical programs. |
Pipeline Progress | Explore Rezolute's promising clinical trials for ersodetug in hyperinsulinism and RZ402 for diabetic macular edema, with key results expected in 2025-2026. |
Metrics to compare | RZLT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRZLTPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.9x | −0.4x | −0.6x | |
PEG Ratio | 0.32 | 0.01 | 0.00 | |
Price / Book | 2.4x | 0.9x | 2.6x | |
Price / LTM Sales | - | 4.4x | 3.1x | |
Upside (Analyst Target) | 173.4% | 160.4% | 55.4% | |
Fair Value Upside | Unlock | 36.6% | 10.2% | Unlock |